Brand name drug sales soar in Canada, while R&D sags

Canada’s manufacturers of brand name medicines have failed to invest 10 per cent of their annual sales into research and development as they have long promised. The industry earned a record $20 billion in 2016, yet spent just four per cent of that on in-house R&D in Canada.

This post was originally published on this site